Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study
Fruquintinib, either as a standalone treatment or in combination with other medications, demonstrates substantial efficacy and favorable tolerability in refractory mCRC patients.
Authors
- Shiyuan Zhou (ORCID: https://orcid.org/0000-0003-2992-789X)
- Wenju Chang (ORCID: https://orcid.org/0000-0003-1182-4083)
- Wensheng Qiu (ORCID: https://orcid.org/0000-0002-9817-1857)
- Shanshan Zeng (ORCID: https://orcid.org/0000-0001-5261-1805)
- Gang Wang (ORCID: https://orcid.org/0000-0002-5842-8080)
- Zhou Zhang (ORCID: https://orcid.org/0000-0002-9639-052X)
- Jianmin Xu (ORCID: https://orcid.org/0000-0001-5441-8240)
- Zhiyong Qin (ORCID: https://orcid.org/0000-0002-7434-7985)
- Qi Feng (ORCID: https://orcid.org/0000-0001-8724-5710)
- Dan Xu (ORCID: https://orcid.org/0000-0002-0648-0100)
- Yang Liu (ORCID: https://orcid.org/0000-0002-7734-5635)
Institutions
- Qingdao University (CN)
- Hebei Medical University (CN)
- Central South University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Second Hospital of Hebei Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- Xiangya Hospital Central South University (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103702
- Citations
- 3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- National Postdoctoral Program for Innovative Talents